Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II trial of vaccination with autologous, irradiated melanoma cells engineered by adenoviral mediated gene transfer to secrete granulocyte-macrophage colony stimulating factor in patients with stage III and IV melanoma.
Sussman TA, Severgnini M, Giobbie-Hurder A, Friedlander P, Swanson SJ, Jaklitsch M, Clancy T, Goguen LA, Lautz D, Swanson R, Daley H, Ritz J, Dranoff G, Hodi FS. Sussman TA, et al. Front Oncol. 2024 May 15;14:1395978. doi: 10.3389/fonc.2024.1395978. eCollection 2024. Front Oncol. 2024. PMID: 38812776 Free PMC article.
Nivolumab maintenance improves overall survival of patients with advanced melanoma who experience severe immune-related adverse events on nivolumab plus ipilimumab.
Maloney AK, Giobbie-Hurder A, Katukota N, Fogarasi MC, Ott PA, Hodi FS, Sussman TA, Silk AW, Haq R, Liu D, Insco M, Buchbinder EI. Maloney AK, et al. Among authors: sussman ta. J Immunother Cancer. 2024 Aug 28;12(8):e009061. doi: 10.1136/jitc-2024-009061. J Immunother Cancer. 2024. PMID: 39209453 Free PMC article.
Safety and efficacy outcomes of early cessation of anti-PD1 therapy in patients 80 years or older: A retrospective cohort study.
Fletcher K, Cortellini A, Ganta T, Kankaria R, Song H, Ye F, Irlmeier R, Debnath N, Saeed A, Radford M, Alahmadi A, Diamond A, Hoimes C, Presley CJ, Owen DH, Abou Alaiwi S, Nassar AH, Lamberti G, Perrone F, Buti S, Giusti R, Filetti M, Vanella V, Mallardo D, Sussman TA, Galetta D, Kalofonou F, Daniels E, Ascierto PA, Pinato DJ, Nebhan C, Berg S, Choueiri TK, Marron TU, Wang Y, Naqash AR, Johnson DB. Fletcher K, et al. Among authors: sussman ta. Cancer Lett. 2024 Aug 1;596:217001. doi: 10.1016/j.canlet.2024.217001. Epub 2024 Jun 3. Cancer Lett. 2024. PMID: 38838764 Free article.
Risk of Thromboembolism in Patients Receiving Immunotherapy-Based Combinations as Front-Line Therapy for Metastatic Renal Cell Carcinoma.
Schuster J, Sheng IY, Reddy CA, Khorana AA, Nizam A, Gupta S, Gilligan T, Wee CE, Sussman TA, Bonham A, Maroli K, Martin A, Ornstein MC. Schuster J, et al. Among authors: sussman ta. Clin Genitourin Cancer. 2024 Apr;22(2):92-97. doi: 10.1016/j.clgc.2023.09.005. Epub 2023 Oct 5. Clin Genitourin Cancer. 2024. PMID: 37932205
Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer: A Multicenter International Cohort Study.
Nebhan CA, Cortellini A, Ma W, Ganta T, Song H, Ye F, Irlmeier R, Debnath N, Saeed A, Radford M, Alahmadi A, Diamond A, Hoimes C, Ramaiya N, Presley CJ, Owen DH, Abou Alaiwi S, Nassar A, Ricciuti B, Lamberti G, Bersanelli M, Casartelli C, Buti S, Marchetti P, Giusti R, Filetti M, Vanella V, Mallardo D, Macherla S, Sussman TA, Botticelli A, Galetta D, Catino A, Pizzutilo P, Genova C, Dal Bello MG, Kalofonou F, Daniels E, Ascierto PA, Pinato DJ, Choueiri TK, Johnson DB, Marron TU, Wang Y, Naqash AR. Nebhan CA, et al. Among authors: sussman ta. JAMA Oncol. 2021 Dec 1;7(12):1856-1861. doi: 10.1001/jamaoncol.2021.4960. JAMA Oncol. 2021. PMID: 34734989 Free PMC article.
18 results